1、White PaperExpanding the Toolbox for Obesity Prevention and Treatment in Low-and Middle-Income Countries:What Does It Take to Make It Happen?DANIEL MORA-BRITO,Engagement Manager,Global Health,EMEA Thought Leadership OLIVIA MEADOWCROFT,Consultant,Obesity Program Manager MOHIT AGARWAL,Consultant,EMEA

2、Thought LeadershipCAROLINE NORBERT,Associate Consultant,EMEA Thought LeadershipTable of contentsIntroduction 1Obesity:Why should we care?2The state of obesity today 2The growing double disease burden in low-and middle-income countries 7The political profile of obesity in noncommunicable diseases-rel

3、ated policy discussions 8Are low-and middle-income countries ready for pharmacotherapeutic 9 approaches to obesity?The rise of anti-obesity agents as a feasible solution to treat and prevent 9 cardiometabolic diseases Market opportunities in low-and middle-income countries:Off-patent semaglutide,10

4、oral anti-obesity medicines,and longer-acting injectables Scaling up the use of anti-obesity medicines in low-and middle-income countries 12Recommendations for cross-sectoral action 21Addressing access barriers to obesity prevention and treatment 21The power of data in optimizing decision-making and

5、 facilitating access 25Conclusions 27References 28About the authors 37Acknowledgements 38 |1The treatment and prevention of obesity from a public health perspective have traditionally been managed through behavioral and policy approaches that promote,in the first dimension,nutrition,physical activit

6、y,and healthier lifestyle choices;and,in the second,taxation or disincentives to the production or wide distribution of unhealthy foods.In recent years,anti-obesity medicines(AOMs)were integrated into the current toolbox of solutions to address this condition,with the advantage of also treating and